Manganese oxide nanomaterials have been widely developed for inducing ferroptosis in cancer and enhancing the efficacy of other treatments such as PDT, CDT, SDT, and PTT (Table 1).[201] A prevalent phenomenon is that these nanoplatforms result in the inactivation of GPX4 and the depletion of GSH, and eventually the generation of a large quantity of ROS. This evidence concerns the gene GPX4 and cancer.